FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Vincent Wai-Sun Wong, Quentin M. Anstee, Louise M. Nitze, Anja Geerts, Jacob George, Victor Nolasco, Mette S. Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu
Formatua:	Artikulua
Hizkuntza:	English
Argitaratua:	Elsevier 2023-12-01
Saila:	EClinicalMedicine
Gaiak:	Biomarkers Clinical trial Non-alcoholic steatohepatitis NASH Semaglutide
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S258953702300487X

Antzeko izenburuak

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
nork: Evgenia Koureta, et al.
Argitaratua: (2024-02-01)

Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
nork: Parth Shah, et al.
Argitaratua: (2024-02-01)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
nork: Jae Seung Lee, et al.
Argitaratua: (2022-04-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
nork: Magdalena Mazurek, et al.
Argitaratua: (2023-02-01)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
nork: Alexander Chaidez, et al.
Argitaratua: (2022-11-01)

Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients
nork: Milićević Anđela, et al.
Argitaratua: (2019-01-01)

Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity
nork: Cacilda Pedrosa de Oliveira, et al.
Argitaratua: (2007-10-01)

Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
nork: Takeshi Horii, et al.
Argitaratua: (2024-11-01)

Semaglutide for the treatment of obesity
nork: Rafał Oleszczuk, et al.
Argitaratua: (2022-01-01)

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
nork: Joseph L. Jilek, et al.
Argitaratua: (2021-12-01)

The efficacy of multi‐disciplinary lifestyle modifications in Taiwanese nonalcoholic steatohepatitis patients
nork: Ming‐Lun Yeh, et al.
Argitaratua: (2024-06-01)

Angiogenic effects of leptin in patients with nonalcoholic steatohepatitis
nork: Gaafar Nagah, et al.
Argitaratua: (2005-01-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
nork: Wesam Bahitham, et al.
Argitaratua: (2024-02-01)

The craze with semaglutide
nork: Ruby Dhar, et al.
Argitaratua: (2024-06-01)

Dose-dependent erythema nodosum after initiation of semaglutide
nork: Jeffrey Sobieraj, MD, et al.
Argitaratua: (2024-05-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
nork: Han Na Jung, et al.
Argitaratua: (2022-03-01)

Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
nork: Hanna Pulaski, et al.
Argitaratua: (2024-09-01)

Spotlight on the Mechanism of Action of Semaglutide
nork: Ilias Papakonstantinou, et al.
Argitaratua: (2024-12-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
nork: Takeshi Hatanaka, et al.
Argitaratua: (2021-10-01)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
nork: Wim Verlinden, et al.
Argitaratua: (2020-11-01)

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
nork: Adam Minich, et al.
Argitaratua: (2022-08-01)

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
nork: Camille Pichon, et al.
Argitaratua: (2022-11-01)

Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
nork: Youwen Tan, et al.
Argitaratua: (2024-12-01)

Semaglutide in the Treatment of Diabetes and Associated Obesity
nork: Rafal Makuch, et al.
Argitaratua: (2024-06-01)

A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
nork: Yikuan Du, et al.
Argitaratua: (2024-10-01)

The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
nork: Tovi Shapira-Furman, et al.
Argitaratua: (2024-08-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
nork: Abdul Haseeb Hasan, et al.
Argitaratua: (2025-01-01)

Contractile Effects of Semaglutide in the Human Atrium
nork: Joachim Neumann, et al.
Argitaratua: (2024-08-01)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
nork: Shruti Tarapure, et al.
Argitaratua: (2021-01-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
nork: Peter Bracha, et al.
Argitaratua: (2024-12-01)

Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
nork: Yang Y, et al.
Argitaratua: (2024-03-01)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
nork: Shu Niu, et al.
Argitaratua: (2022-12-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
nork: Takahiro Iijima, et al.
Argitaratua: (2023-06-01)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
nork: Mansoor Husain, et al.
Argitaratua: (2020-09-01)

Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis
nork: Chaoyang Wang, et al.
Argitaratua: (2023-10-01)

Nonobese mice with nonalcoholic steatohepatitis fed on a choline‐deficient, l‐amino acid‐defined, high‐fat diet exhibit alterations in signaling pathways
nork: Noriko Suzuki‐Kemuriyama, et al.
Argitaratua: (2021-11-01)

The Discovery and Development of Liraglutide and Semaglutide
nork: Lotte Bjerre Knudsen, et al.
Argitaratua: (2019-04-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
nork: Louis Talay, et al.
Argitaratua: (2024-10-01)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
nork: Xiaoyi Chen, et al.
Argitaratua: (2023-03-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
nork: Souradipta Ganguly, et al.
Argitaratua: (2021-01-01)